The short answer
Systemic cyclosporine can lower magnesium, so guidance supports checking magnesium before and periodically during treatment. Supplementation should follow measured need; the evidence does not establish that everyone taking cyclosporine needs magnesium.
What this answer covers
Applies to oral or intravenous cyclosporine, not eye drops; replacement and monitoring depend on the treatment setting.
- Supplement or preparation
- Magnesium
- Medication ingredient
- cyclosporine
Evidence and practical considerations
Timing & monitoring
Systemic cyclosporine guidance and monitoring references support laboratory monitoring of magnesium because hypomagnesemia and renal magnesium wasting occur. Routine universal supplementation is not established; replacement is status-directed. Adjudication lead: supported monitoring, conditional supplementation. Animal, in-vitro, product, route, and formulation boundaries were applied without silent extrapolation.
- Exact scope
- magnesium with cyclosporine
- Medication form and route
- systemic oral or intravenous cyclosporine; ophthalmic use excluded
- Timing or duration
- Check magnesium at baseline and periodically during therapy; replacement is status-directed, not automatically universal.
What remains uncertain
- Exact cyclosporine RxCUI 3008 IN is preserved; precise ingredients, salts, combinations, and other calcineurin inhibitors are not silently merged.
- Modified and nonmodified systemic finished products remain distinct unless the source explicitly bridges active moiety and formulation.
- Systemic evidence is not transferred to ophthalmic cyclosporine.
- Preclinical plausibility is not treated as a human clinical interaction; no conflicting_evidence decision is used without genuinely opposing exact endpoints.
Factors that may matter: baseline magnesium and renal wasting; transplant phase and cyclosporine exposure; other magnesium-lowering factors; local monitoring protocol.
Read the supporting source summaries
Source 1: clinical review or professional reference
ncbi.nlm.nih.gov · Source check Jul 25, 2026
Population: Systemic cyclosporine recipients, with transplant-specific drug-monitoring ranges.
Magnesium and renal function require monitoring; time-specific transplant trough targets are given because underexposure and toxicity matter.
Secondary review, not a magnesium-supplement trial; targets depend on organ, assay, regimen, and protocol.
Source 2: professional monitoring guidance
sps.nhs.uk · Source check Jul 25, 2026
Population: Patients prescribed systemic ciclosporin under specialist monitoring.
Guidance explicitly includes baseline and periodic magnesium and potassium with trend review.
Consensus guidance, not proof that universal supplementation improves outcomes; frequency varies by indication.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Research summary published |
Article revision: f849f64249a35f46
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.